In a 35-year-old pregnant woman with known epilepsy on levetiracetam 500 mg twice daily who had a seizure 15 days ago, what is the appropriate management?

Management of Breakthrough Seizure in Pregnant Woman on Levetiracetam

Increase the levetiracetam dose immediately based on therapeutic drug monitoring (TDM), as pregnancy significantly reduces levetiracetam levels and breakthrough seizures indicate inadequate drug exposure.

Immediate Actions

The single seizure 15 days ago signals that the current dose of levetiracetam 500 mg twice daily is insufficient. Pregnancy causes substantial decreases in levetiracetam concentration-dose ratios throughout gestation, with the most significant decline occurring in the third trimester 1, 2. This patient requires urgent dose optimization.

Key Steps:

1. Obtain serum levetiracetam level immediately - Trough level (before morning dose) is preferred
2. Compare to pre-pregnancy baseline if available, or establish therapeutic target now
3. Increase dose empirically while awaiting levels - Do not wait for lab results to adjust therapy

Dose Adjustment Strategy

For patients with breakthrough seizures during pregnancy, maintain levetiracetam concentration above 65% of pre-pregnancy levels 1. If no baseline exists, target therapeutic range of 12-46 mg/L, though most pregnant patients fall below this range 2.

Practical Dosing Approach:

• Increase current dose by 50-100% (from 1000 mg/day to 1500-2000 mg/day total)
• Consider four-times-daily dosing rather than twice daily, as nocturnal breakthrough seizures suggest inadequate overnight coverage 3
• Monthly TDM throughout pregnancy is essential - concentration-dose ratios decline progressively 4, 2

Critical Monitoring Protocol

Monthly serum level monitoring is mandatory, not optional 5, 4. The evidence shows:

• Levetiracetam clearance increases significantly during pregnancy 6
• 93.8% of samples in pregnant women fall below therapeutic range 2
• Seizure frequency correlates directly with low drug levels in non-seizure-free patients 1

Monitoring Schedule:

• Monthly trough levels through delivery
• Dose adjustment whenever level drops below target
• More frequent monitoring (every 2 weeks) if seizures recur

Folic Acid Supplementation

Prescribe folic acid 4 mg daily immediately if not already taking 7. This high-dose supplementation is specifically recommended for women with epilepsy on antiepileptic drugs due to increased neural tube defect risk, and should have been initiated pre-conception but must be started now.

Safety Considerations

Levetiracetam is the preferred antiepileptic drug in pregnancy due to low teratogenic potential 6, 5. The FDA label indicates:

• Pregnancy Category C
• No evidence of major malformations at therapeutic doses in humans
• Benefits of seizure control outweigh theoretical risks 6

Seizure control is paramount - maternal seizures pose greater risk to fetus than levetiracetam exposure, including:

• Fetal hypoxia
• Placental abruption
• Preterm delivery
• Fetal injury 7

Common Pitfalls to Avoid

1. Do not maintain pre-pregnancy dose - physiologic changes mandate dose increases
2. Do not rely on clinical assessment alone - breakthrough seizure proves inadequate levels
3. Do not switch medications - levetiracetam remains safest option; optimize current therapy
4. Do not delay dose adjustment - waiting for "next appointment" risks further seizures
5. Do not use twice-daily dosing if nocturnal seizures occur - consider 3-4 times daily 3

Postpartum Planning

Document current pregnancy dose adjustments for postpartum taper planning. Rapid dose reduction will be needed after delivery as clearance normalizes, typically requiring adjustments at days 1,7, and 21 postpartum 8. Failure to reduce dose postpartum risks toxicity.

Neurology Consultation

Immediate neurology or maternal-fetal medicine consultation is warranted given breakthrough seizure during pregnancy. Collaborative management ensures optimal outcomes for both mother and fetus, particularly if seizures continue despite dose optimization.

The evidence strongly supports aggressive dose escalation guided by TDM rather than conservative "wait and see" approaches in pregnant women with breakthrough seizures on levetiracetam 4, 1, 2, 3.